Investigation of community pharmacists' knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice.

Pharmacist Pharmacogenetics Pharmacogenomics testing UAE

Journal

Human genomics

ISSN: 1479-7364

Titre abrégé: Hum Genomics

Pays: England

ID NLM: 101202210

Informations de publication

Date de publication:
30 Jan 2024

Historique:

received: 05 10 2023

accepted: 22 01 2024

medline: 31 1 2024

pubmed: 31 1 2024

entrez: 30 1 2024

Statut: epublish

Résumé

Community pharmacists must be well-equipped to advance pharmacogenomics services. Nevertheless, limited data is available regarding pharmacists' knowledge and attitudes toward pharmacogenomics testing. The present study aimed to evaluate community pharmacists' knowledge and attitudes toward pharmacogenomics testing in the UAE. In this cross-sectional study, a validated, online, self-administered survey, was randomly distributed to community pharmacists across the United Arab Emirates (UAE). The participants demonstrated poor knowledge about pharmacogenomic testing (median score < 8). Having 10-29 (Adjusted odds ration [AOR]: 0.038; 95% CI: 0.01-0.146, p = 0.001) and 30-49 (AOR: 0.097; 95% CI: 0.04-0.237, p = 0.001) patients per day was associated with poorer knowledge. Also, receiving 10-29 (AOR: 0.046; 95% CI: 0.005-0.401, p = 0.005), 30-49 (AOR: 0.025; 95% CI: 0.003-0.211, p = 0.001), and > 50 (AOR: 0.049; 95% CI: 0.005-0.458, p = 0.008) prescriptions decreased the odds of having good knowledge. Around half (43.9%) of the participants did not show a positive attitude toward pharmacogenomic testing (median score < 11). Having 30-49 patients per day (AOR: 5.351; 95% CI: 2.414-11.860, p = 0.001) increased the odds of good knowledge while receiving 10-29 (AOR: 0.133; 95% CI: 0.056-0.315, p = 0.001) and 30-49 (AOR: 0.111; 95% CI: 0.049-0.252, p = 0.001) prescriptions a day were associated with decreased odds of positive attitude toward the pharmacogenomics testing. The findings indicate a lack of knowledge and less-than-ideal attitudes among community pharmacists regarding pharmacogenomics testing. Enhanced efforts focused on educational initiatives and training activities related to pharmacogenomics testing is needed. Additionally, reducing workload can facilitate better knowledge acquisition and help mitigate unfavorable attitudes.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

In this cross-sectional study, a validated, online, self-administered survey, was randomly distributed to community pharmacists across the United Arab Emirates (UAE).

RESULTS RESULTS

The participants demonstrated poor knowledge about pharmacogenomic testing (median score < 8). Having 10-29 (Adjusted odds ration [AOR]: 0.038; 95% CI: 0.01-0.146, p = 0.001) and 30-49 (AOR: 0.097; 95% CI: 0.04-0.237, p = 0.001) patients per day was associated with poorer knowledge. Also, receiving 10-29 (AOR: 0.046; 95% CI: 0.005-0.401, p = 0.005), 30-49 (AOR: 0.025; 95% CI: 0.003-0.211, p = 0.001), and > 50 (AOR: 0.049; 95% CI: 0.005-0.458, p = 0.008) prescriptions decreased the odds of having good knowledge. Around half (43.9%) of the participants did not show a positive attitude toward pharmacogenomic testing (median score < 11). Having 30-49 patients per day (AOR: 5.351; 95% CI: 2.414-11.860, p = 0.001) increased the odds of good knowledge while receiving 10-29 (AOR: 0.133; 95% CI: 0.056-0.315, p = 0.001) and 30-49 (AOR: 0.111; 95% CI: 0.049-0.252, p = 0.001) prescriptions a day were associated with decreased odds of positive attitude toward the pharmacogenomics testing.

CONCLUSIONS CONCLUSIONS

The findings indicate a lack of knowledge and less-than-ideal attitudes among community pharmacists regarding pharmacogenomics testing. Enhanced efforts focused on educational initiatives and training activities related to pharmacogenomics testing is needed. Additionally, reducing workload can facilitate better knowledge acquisition and help mitigate unfavorable attitudes.

Identifiants

DOI: 10.1186/s40246-024-00574-z PMID: 38291455

pubmed: 38291455

doi: 10.1186/s40246-024-00574-z

pii: 10.1186/s40246-024-00574-z

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Konig IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J. 2017;50(4):1700391.

doi: 10.1183/13993003.00391-2017 pubmed: 29051268

Oates JT, Lopez D. Pharmacogenetics: an important part of drug development with a focus on its application. Int J Biomed Investig. 2018;1(2):111.

pubmed: 32467882 pmcid: 7255432

Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008;77(11):1553–60.

pubmed: 18581835

Cacabelos R. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett. 2020;726: 133807.

doi: 10.1016/j.neulet.2018.09.018 pubmed: 30236877

Wang X, Wang C, Zhang Y, An Z. Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT. BMC Psychiatry. 2023;23(1):334.

doi: 10.1186/s12888-023-04756-2 pubmed: 37173736 pmcid: 10176803

Rendell T, Barnett J, Wright D. Co-designing a community pharmacy pharmacogenomics testing service in the UK. BMC Health Serv Res. 2022;22(1):378.

doi: 10.1186/s12913-022-07730-y pubmed: 35317803 pmcid: 8939480

Hansen JM, Norgaard J, Kalvemark SS. A systematic review of pharmacogenetic testing in primary care: attitudes of patients, general practitioners, and pharmacists. Res Social Adm Pharm. 2022;18(8):3230–8.

doi: 10.1016/j.sapharm.2021.12.002 pubmed: 34996718

Yau AAAA, Haque M. Knowledge, attitude and practice concerning pharmacogenomics among pharmacists: a systematic review. J Young Pharm. 2015;7(3):145–54.

doi: 10.5530/jyp.2015.3.3

Al-Gazali L, Ali BR. Mutations of a country: a mutation review of single gene disorders in the United Arab Emirates (UAE). Hum Mutat. 2010;31(5):505–20.

doi: 10.1002/humu.21232 pubmed: 20437613

Bizzari S, Nair P, Hana S, Deepthi A, Al-Ali MT, Al-Gazali L, et al. Spectrum of genetic disorders and gene variants in the United Arab Emirates national population: insights from the CTGA database. Front Genet. 2023;14:1177204.

doi: 10.3389/fgene.2023.1177204 pubmed: 37214420 pmcid: 10194840

Rahma AT, Elsheik M, Ali BR, Elbarazi I, Patrinos GP, Ahmed LA, et al. Knowledge, attitudes, and perceived barriers toward genetic testing and pharmacogenomics among healthcare workers in the united arab emirates: a cross-sectional study. J Pers Med. 2020;10(4):216.

doi: 10.3390/jpm10040216 pubmed: 33182317 pmcid: 7711841

Muflih S, Alshogran OY, Al-Azzam S, Al-Taani G, Khader YS. Physicians’ knowledge and attitudes regarding point-of-care pharmacogenetic testing: a hospital-based cross-sectional study. Pharmgenomics Pers Med. 2021;14:655–65.

pubmed: 34103970 pmcid: 8179816

rahma AT, elbarazi i, ali br, patrinos gp, ahmed la, al maskari f. genomics and pharmacogenomics knowledge, attitude and practice of pharmacists working in United Arab Emirates: findings from focus group discussions-a qualitative study. J Pers Med. 2020;10(3):134.

doi: 10.3390/jpm10030134 pubmed: 32962013 pmcid: 7563679

Alrabiah Z, Syed W, Babelghaith SD, Al Arifi MN. Clinical knowledge, attitude, and perceptions of community pharmacists toward pharmacogenomics - a cross-sectional study from Saudi Arabia. Pharmgenomics Pers Med. 2023;16:433–41.

pubmed: 37187880 pmcid: 10179052

Roederer MW, Van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Per Med. 2012;9(1):19–27.

doi: 10.2217/pme.11.87 pubmed: 29783293

Bagher AM, Neamatallah T, Balto G, Almikhy L, Almutairi SS, Abushal MO, et al. Knowledge, perception, and confidence of hospital pharmacists toward pharmacogenetics in Jeddah, Kingdom of Saudi Arabia. Saudi Pharm J. 2021;29(1):53–8.

doi: 10.1016/j.jsps.2020.12.006 pubmed: 33603539

Ahmed NJ, Alrawili AS, Alkhawaja FZ. Knowledge and awareness on personalized medicine amongst health care specialists and university students in health colleges in Saudi Arabia. J Pharm Res Int. 2020;32(16):177–83.

doi: 10.9734/jpri/2020/v32i1630741

Albitar L, Alchamat GA. Pharmacogenetics: Knowledge assessment amongst Syrian pharmacists and physicians. BMC Health Serv Res. 2021;21(1):1031.

doi: 10.1186/s12913-021-07040-9 pubmed: 34592972 pmcid: 8485485

Abubakar U, Subramaniam L, Ayinla A, Ambali MN, Mohamed Noor DA, Daud NAA, et al. Knowledge, attitude and perception of community pharmacists toward pharmacogenomics services in northern Nigeria: a cross-sectional study. J Pharm Policy Pract. 2022;15(1):39.

doi: 10.1186/s40545-022-00435-x pubmed: 35614463 pmcid: 9134695

Athiyah U, Setiawan CD, Nugraheni G, Zairina E, Utami W, Hermansyah A. Assessment of pharmacists’ knowledge, attitude and practice in chain community pharmacies toward their current function and performance in Indonesia. Pharm Pract (Granada). 2019;17(3):1518.

doi: 10.18549/PharmPract.2019.3.1518 pubmed: 31592292

Jarrar Y, Musleh R, Ghanim M, AbuKhader I, Jarrar Q. Assessment of the need for pharmacogenomics education among pharmacists in the West Bank of Palestine. Int J Clin Pract. 2021;75(9): e14435.

doi: 10.1111/ijcp.14435 pubmed: 34191402

Albassam A, Alshammari S, Ouda G, Koshy S, Awad A. Knowledge, perceptions and confidence of physicians and pharmacists toward pharmacogenetics practice in Kuwait. PLoS ONE. 2018;13(9): e0203033.

doi: 10.1371/journal.pone.0203033 pubmed: 30183746 pmcid: 6124749

Alhaddad ZA, AlMousa HA, Younis NS. Pharmacists’ Knowledge, and Insights in Implementing Pharmacogenomics in Saudi Arabia. Int J Environ Res Public Health. 2022;19(16):10073.

doi: 10.3390/ijerph191610073 pubmed: 36011723 pmcid: 9407761

Hayashi M, Mahmoud SH, Hamdy DA. The efficacy of a didactic and case-based pharmacogenomics education program on improving the knowledge and confidence of alberta pharmacists. Pharmgenomics Pers Med. 2022;15:409–27.

pubmed: 35496350 pmcid: 9045709

Haga SB, Mills R, Moaddeb J. Evaluation of a pharmacogenetic educational toolkit for community pharmacists. Pharmacogenomics. 2016;17(14):1491–502.

doi: 10.2217/pgs-2016-0002 pubmed: 27533631 pmcid: 5220456

Australasia RCoPo. 2018. Position Statement [Internet] Available from: https://www.rcpaeduau/Library/College-Policies/Position-Statements/Utilisation-of-pharmacogenetics-in-healthcare

Aldosari H, Alsairafi Z, Waheedi S. Continuing education in pharmacy: A cross-sectional study exploring pharmacists’ attitudes and perceptions. Saudi Pharm J. 2020;28(7):803–13.

doi: 10.1016/j.jsps.2020.05.008 pubmed: 32647481 pmcid: 7335716

Da P, Sl N, Bp S, Ts K. Knowledge, awareness and attitude of pharmacists toward pharmacogenetic practice: perspective of community and hospital in Yogyakarta, Indonesia. J Commun Med Health Education. 2017;7(6):1–10.

doi: 10.4172/2161-0711.1000568

Shao SC, Chan YY, Lin SJ, Li CY, Kao Yang YH, Chen YH, et al. Workload of pharmacists and the performance of pharmacy services. PLoS ONE. 2020;15(4): e0231482.

doi: 10.1371/journal.pone.0231482 pubmed: 32315319 pmcid: 7173874

Frigon MP, Blackburn ME, Dubois-Bouchard C, Gagnon AL, Tardif S, Tremblay K. Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients. Pharmacogenomics. 2019;20(8):589–98.

doi: 10.2217/pgs-2019-0004 pubmed: 31190623

Luzum JA, Luzum MJ. Physicians’ attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Per Med. 2016;13(2):119–27.

doi: 10.2217/pme.15.57 pubmed: 29749904 pmcid: 5907693

Haga SB, Mills R, Moaddeb J, Liu Y, Voora D. Independent community pharmacists’ experience in offering pharmacogenetic testing. Pharmgenomics Pers Med. 2021;14:877–86.

pubmed: 34290521 pmcid: 8289463

Kisor DF, Petry NJ, Bright DR. Pharmacogenomics in the United States community pharmacy setting: the Clopidogrel-CYP2C19 Example. Pharmgenomics Pers Med. 2021;14:569–77.

pubmed: 34040417 pmcid: 8140945

Karuna N, Tragulpiankit P, Mahasirimongkol S, Chumnumwat S. Knowledge, attitude, and practice toward pharmacogenomics among hospital pharmacists in Thailand. Pharmacogenet Genomics. 2020;30(4):73–80.

doi: 10.1097/FPC.0000000000000399 pubmed: 32187156